Difference between revisions of "GAPLINC"
Jiabao Cao (talk | contribs) |
Jiabao Cao (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
===Function=== | ===Function=== | ||
| − | Manipulating GAPLINC expression alters CD44 mRNA abundance and the effects of GAPLINC on cell migration and proliferation are neutralized by suppressing CD44 expression. And GAPLINC regulates CD44 as a molecular decoy for miR211-3p, a microRNA that targets both CD44 and GAPLINC. Tissue ISH analysis suggests that GAPLINC overexpression defines a subgroup of patients with gastric cancer with very poor survival. | + | Manipulating GAPLINC expression alters CD44 mRNA abundance and the effects of GAPLINC on cell migration and proliferation are neutralized by suppressing CD44 expression. And GAPLINC regulates CD44 as a molecular decoy for miR211-3p, a microRNA that targets both CD44 and GAPLINC. Tissue ISH analysis suggests that GAPLINC overexpression defines a subgroup of patients with gastric cancer with very poor survival.<ref name="ref1" /> |
===Expression=== | ===Expression=== | ||
| + | [[File:GAPLINC exp.JPG|right|thumb|400px|'''The expression in gastric cancer and normal tissue ''' <ref name="ref1" />.]] | ||
The expression levels of GAPLINC is most upregulated in gastric cancer compared with normal tissue based on ISH. In addition, GAPLINC expression correlates with poor outcome of gastric cancers.<ref name="ref1" /> | The expression levels of GAPLINC is most upregulated in gastric cancer compared with normal tissue based on ISH. In addition, GAPLINC expression correlates with poor outcome of gastric cancers.<ref name="ref1" /> | ||
| + | |||
===Diseases=== | ===Diseases=== | ||
Gastric cancer<ref name="ref1" /> | Gastric cancer<ref name="ref1" /> | ||
Latest revision as of 13:21, 26 January 2018
Contents
Annotated Information
Name
GAPLINC:gastric adenocarcinoma predictive long intergenic noncoding RNA
Characteristics
GAPLINC is a 924-bp-long lncRNA that is highly expressed in gastric cancer tissues[1]
Function
Manipulating GAPLINC expression alters CD44 mRNA abundance and the effects of GAPLINC on cell migration and proliferation are neutralized by suppressing CD44 expression. And GAPLINC regulates CD44 as a molecular decoy for miR211-3p, a microRNA that targets both CD44 and GAPLINC. Tissue ISH analysis suggests that GAPLINC overexpression defines a subgroup of patients with gastric cancer with very poor survival.[1]
Expression
The expression levels of GAPLINC is most upregulated in gastric cancer compared with normal tissue based on ISH. In addition, GAPLINC expression correlates with poor outcome of gastric cancers.[1]
Diseases
Gastric cancer[1]
Sequence
>gi|578888097|ref|NR_110429.1| Homo sapiens gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA (GAPLINC), transcript variant 1, long non-coding RNA
000081 CAAGAAATCT GTTTTGAAGC TTCTCTGCGT TCACACACAG CAGCCTGGTT TCCTGGAAGG GCATTTTCCA CATTGTGCGT 000160
000161 TATGGATGAT CATCCCAGGC ATCAGGTGTG AAGCCCTGCA TCCACATCCA GGGGCTATCA AATCTCTCTG CAAAAGGAGA 000240
000241 AGCTGGACTC AGGCACGTTT ACAGTGATGT GTATGCAGGG TATGCACAGA TGTGGAAACA GGAACTGATG TGTCCATTAC 000320
000321 ACCACTAGGA CAGAGGCCAG AACAATGAAG AAACCAAATA CTTGGAAGAG GGTAGAGATA ATGAATGGAG TCCAAGAGCC 000400
000401 CTGATTGTGC CATAAATGTC CAGATAATTC CATACCTGAG GATTATGTGG TTTGTAAACT TGGCACTTAG AAGAACCAAT 000480
000481 AAAATCATGT TATAGTTTCA AAAAAAAAAA A
Labs working on this lncRNA
- State Key Laboratory for Oncogenes and Related Genes; Division of Gastroenterology and Hepatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
